Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Collateral Damage From the COVID-19 Pandemic Observed in Patients Treated With Intravitreal Injections (IVT) of Anti-angiogenic Agents

NCT04395859 is registered in ClinicalTrials.gov with Fondation Ophtalmologique Adolphe de Rothschild as lead sponsor.

NCT NCT04395859
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04395859 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Collateral Damage From the COVID-19 Pandemic Observed in Patients Treated With Intravitreal Injections (IVT) of Anti-angiogenic Agents
Lead sponsor
Fondation Ophtalmologique Adolphe de Rothschild
Phase
Observational
Overall status
Completed
Start date
May 27, 2020
Completion date
February 15, 2022
Enrollment
233 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

age related macular degeneration, diabetic macular edema, retinal vein occlusion